Zachary Michael Jacobsen, CRNA Nurse Anesthetist, Certified Registered Medicare: Medicare Enrolled Practice Location: 900 Sunset Dr, La Grande, OR 97850 Phone: 541-963-8421 |
Bradley Robert Close, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 900 Sunset Dr, La Grande, OR 97850 Phone: 541-963-8421 Fax: 541-963-1476 |
Sheridan D Klinger, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 900 Sunset Dr, La Grande, OR 97850 Phone: 541-963-1401 Fax: 541-963-1502 |
News Archive
A collaborative team of researchers including scientists from UCLA has uncovered evidence that a specific genetic alteration appears to contribute to disorders of brain development, including schizophrenia. They also found that schizophrenia shares a common biological pathway with Fragile X mental retardation syndrome, a disorder associated with both intellectual impairment and autism.
Islamic Relief USA, a Washington, D.C.-based relief and development organization, today announced that it has increased its fundraising goal for the Pakistan flood victims to $4 million due to the worsening conditions in the region. It has also collected more than $23 million in in-kind donations.
UCLA researchers have found that doctors can use a specific antibiotic in addition to surgically draining an abscess to give people a better chance of recovery. The discovery turns on its head the long-held notion that surgical drainage alone is sufficient for treating abscesses.
Results from a clinical study conducted at the Temple University School of Medicine and published today in the journal Postgraduate Medicine(1), show that a pre-packaged, portion controlled meal plan helped overweight individuals with type 2 diabetes lose significantly more weight and reduce their A1C test scores (a 90-day measure of blood sugar control) by almost a full point greater than those following a standard hospital-based diabetes support and education program, according to the findings.
Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.
› Verified 2 days ago